A Safety, Tolerability, and Pharmacokinetic Study of Single, Escalating Subcutaneous Doses of LY2951742 in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 30 Jun 2013
At a glance
- Drugs Galcanezumab (Primary)
- Indications Migraine; Pain
- Focus Adverse reactions
- 30 Jun 2013 Results presented at the 2013 International Headache Congress .
- 18 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Mar 2012 Planned end date changed from 1 Feb 2012 to 1 Apr 2012 as reported by ClinicalTrials.gov.